IP Library Granted Patent US 8,084,462
Granted Patent B2
US 8,084,462 · App. 12/793,773 · Granted Dec 27, 2011

3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,084,462
App. No.
12/793,773
Granted
Dec 27, 2011
Kind
B2
Abstract

The present invention relates to the pharmaceutical compositions incorporating compounds capable of affecting nicotinic acetylcholinergic receptors (nAChRs), for example, as modulators of specific nicotinic receptor subtypes (specifically, the α7 nAChR subtype). The present invention also relates to methods for treating a wide variety of conditions and disorders, particularly those associated with dysfunction of the central and autonomic nervous systems.

Claims (2)

1. A method of ameliorating one or more symptoms associated with schizophrenia comprising administering to a subject in need thereof a therapeutically effective amount of (R,R; R,S; S,R; and 8,S)—N-(2-((3-pyridinyl)methyl)=1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide or a pharmaceutically acceptable salt thereof.

2. A method of delaying onset or progression of one or more symptoms associated with schizophrenia, comprising administering to a subject in need thereof a therapeutically effective amount of (R,R; R,S; S,R; and S,S)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide or a pharmaceutically acceptable salt thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2016
From: CATALYST BIOSCIENCES, INC.
To: ATTENUA, INC.
Reel/Frame 039688/0771 →
CHANGE OF NAME Recorded Aug 11, 2016
From: TARGACEPT , INC.
To: CATALYST BIOSCIENCES, INC.
Reel/Frame 039646/0595 →